Tolerability and positive efficacy results after subcutaneous immunotherapy with Parietaria judaica depot extract
Por:
Enrique E, de Rojas DH, Alba P, Flores I, Colomer N, Andreu C, Gómez-Fernández MC, Landeta A, Asturias JA, Martínez A and Madariaga-Goirigolzarri B
Publicada:
1 oct 2018
Resumen:
Aim: To evaluate tolerability and efficacy of Parietaria judaica subcutaneous immunotherapy on patients with allergic rhinoconjunctivitis. Patients & methods: 51 patients were assigned to build-up scheme (six increasing doses) of P. judaica depot native extract, plus three maintenance monthly administrations. Results: Out of 470 administered doses, only 3.8% elicited systemic reactions (1.5% nonspecific and 2.3% grade I). Concerning the exploratory efficacy parameters: cutaneous reactivity at the final visit versus baseline was significantly decreased; specific titers of IgG and IgG4 increased significantly and patients showed a significant decrease in the rhinitis symptoms score. Conclusion:P. judaica subcutaneous immunotherapy (Allergovac((R)) depot ROXALL Medicina Espana S.A., Zamudio, Spain) with an abbreviated up-dosing scheme showed an adequate safety and tolerability profile and induced preliminary efficacy changes.
Filiaciones:
:
Allergy Department, Hospital de Sagunto, Sagunto 46500, Spain
de Rojas DH:
Allergy Department, IIS, Hospital Universitari La Fe, Valencia 46009, Spain
Alba P:
Allergy Department, Hospital de Manises, Manises 46940, Spain
:
Allergy Department, Hospital Vega Baja, Orihuela 03314, Spain
Colomer N:
Allergy Department, IIS, Hospital Universitari La Fe, Valencia 46009, Spain
:
Allergy Department, Hospital Vega Baja, Orihuela 03314, Spain
Gómez-Fernández MC:
ROXALL España, RD Department, Zamudio 48170, Spain
Landeta A:
ROXALL España, RD Department, Zamudio 48170, Spain
Asturias JA:
ROXALL España, RD Department, Zamudio 48170, Spain
Martínez A:
ROXALL España, RD Department, Zamudio 48170, Spain
Madariaga-Goirigolzarri B:
ROXALL España, RD Department, Zamudio 48170, Spain
|